Is regorafenib a chemotherapy?

Regorafenib is the generic name for the trade name chemotherapy drug Stivarga®. In some cases, health care professionals may use the trade name Stivarga® when referring to the generic drug name regorafenib.

How long do people live on Lonsurf?

The median number of cycles of Lonsurf administered was 3. Median follow-up was 6.0 months, with all patients deceased at the time of analysis. Median progression-free survival (PFS) was 3.2 months, and overall survival (OS) was 5.8 months.

Is regorafenib FDA approved?

On April 27, the Food and Drug Administration (FDA) approved regorafenib (Stivarga®) for some patients with hepatocellular carcinoma (HCC), the most common form of liver cancer.

How long can you take regorafenib?

How long will I be taking STIVARGA? The recommended dose of STIVARGA is 160 mg (four 40-mg tablets) every day for 3 weeks, followed by a 1-week break. This is 1 cycle of treatment. Your doctor may stop your treatment or change the dose.

How long does STIVARGA extend life?

Improvement in Overall Survival Patients taking STIVARGA (379) lived a median of 10.6 months compared to those taking placebo (194) who lived a median of 7.8 months.

Is LONSURF a last resort?

Oncologist has told him Lonsurf is the last treatment he can routinely prescribe and after that only option would be to be referred for trials.

Can LONSURF shrink tumors?

Lonsurf, previously known as TAS-102, is a combination of two drugs called trifluridine and Tipiracil hydrochloride. Trifluridine is taken into the DNA of tumour cells and inhibits tumour growth.

How long can you take Stivarga?

What is regorafenib approved?

The US Food and Drug Administration (FDA) has approved the multikinase inhibitor regorafenib (Stivarga) to treat patients with colorectal cancer that has metastasized following previous treatment.

Who makes regorafenib?

Stivarga (Regorafenib) is an oral multikinase inhibitor developed by Bayer HealthCare for the treatment of metastatic colorectal cancer (mCRC). The US Food and Drug Administration (FDA) approved Stivarga in September 2012 for the treatment of mCRC patients.